These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 38832710)

  • 21. Genotypic and predicted phenotypic analysis of SARS-COV-2 Omicron subvariants in immunocompromised patients with COVID-19 following tixagevimab-cilgavimab prophylaxis.
    Ordaya EE; Vergidis P; Razonable RR; Yao JD; Beam E
    J Clin Virol; 2023 Mar; 160():105382. PubMed ID: 36731147
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Evaluating tixagevimab/cilgavimab prophylaxis in allogeneic haematopoietic cell transplantation recipients for COVID-19 prevention.
    Trepl J; Pasin C; Schneidawind D; Mueller NJ; Manz MG; Bankova AK; Abela IA
    Br J Haematol; 2024 May; 204(5):1908-1912. PubMed ID: 38327109
    [TBL] [Abstract][Full Text] [Related]  

  • 23. SARS-CoV-2 Pre-Exposure Prophylaxis with Sotrovimab and Tixagevimab/Cilgavimab in Immunocompromised Patients-A Single-Center Experience.
    Totschnig D; Augustin M; Niculescu I; Laferl H; Jansen-Skoupy S; Lehmann C; Wenisch C; Zoufaly A
    Viruses; 2022 Oct; 14(10):. PubMed ID: 36298832
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Breakthrough SARS-CoV-2 infections among recipients of tixagevimab-cilgavimab prophylaxis: A citywide real-world effectiveness study.
    Lendacki FR; Li L; Forrest GN; Jordan L; Zelinski C; Black SR; Ison MG; Seo JY
    Transpl Infect Dis; 2024 Feb; 26(1):e14194. PubMed ID: 37987112
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy and safety of tixagevimab-cilgavimab as pre-exposure prophylaxis for COVID-19: A systematic review and meta-analysis.
    Soeroto AY; Yanto TA; Kurniawan A; Hariyanto TI
    Rev Med Virol; 2023 Mar; 33(2):e2420. PubMed ID: 36617704
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Tixagevimab/Cilgavimab does not prevent COVID-19 in patients with multiple sclerosis and related disorders on B-cell depleting therapies.
    Conway S; Gupta S; Healy B; Chuang TY; Stazzone L; Sullivan J; Polgar-Turcsanyi M; Chitnis T; Houtchens M
    Mult Scler Relat Disord; 2024 Jul; 87():105680. PubMed ID: 38795595
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy and safety of tixagevimab-cilgavimab versus SARS-CoV-2 breakthrough infection in the hematological conditions.
    Duminuco A; Nardo A; Orofino A; Giunta G; Conticello C; Del Fabro V; Chiarenza A; Parisi MS; Figuera A; Leotta S; Milone G; Cupri A; Cambria D; Di Raimondo F; Romano A; Palumbo GA
    Cancer; 2024 Jan; 130(1):41-50. PubMed ID: 37658645
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effectiveness of tixagevimab/cilgavimab in patients with hematological malignancies as a pre-exposure prophylaxis to prevent severe COVID-19: a Czech retrospective multicenter study.
    Demel I; Skopal D; Šafránková E; Rozsívalová P; Jindra P; Šrámek J; Turková A; Vydra J; Labská K; Vedrová J; Čerňan M; Szotkowski T; Móciková H; Hynková L; Šušol O; Kováčová I; Belada D; Hájek R
    Ann Hematol; 2024 Mar; 103(3):981-992. PubMed ID: 38092996
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pre-exposure prophylaxis with tixagevimab/cilgavimab for coronavirus disease 2019 (COVID-19) during the Omicron BA.5 wave at a single institution in Japan.
    Kawashima I; Hyuga H; Nakadate A; Matsuura M; Sakamoto Y; Suzuki J; Kumagai T; Suzuki M; Koshiishi M; Yamamoto T; Nakajima K; Tanaka M; Kirito K
    Int J Hematol; 2023 Dec; 118(6):731-736. PubMed ID: 37747583
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Nephrotic-range proteinuria: a potential risk factor for failure of tixagevimab-cilgavimab prophylaxis.
    Al Jurdi A; El Mouhayyar C; Efe O; Jeyabalan A; Riella LV
    J Nephrol; 2024 Jan; 37(1):141-147. PubMed ID: 37658973
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Tixagevimab-Cilgavimab Decreases the Rate of SARS-CoV-2 Infection Among Solid Organ Transplant Recipients.
    Sanayei AM; Montalvan A; Faria I; Ochalla J; Pavlakis M; Blair BM; Alonso CD; Curry M; Saberi B
    Transplant Proc; 2023 Oct; 55(8):1784-1792. PubMed ID: 37661468
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Predictors of SARS-CoV-2 Omicron breakthrough infection after receipt of AZD7442 (tixagevimab-cilgavimab) for pre-exposure prophylaxis among hematologic malignancy patients.
    Laracy JC; Yan J; Steiger SN; Tan CA; Cohen N; Robilotti EV; Fender J; Cohen S; Korde N; Lee-Teh M; Noy A; Oved JH; Roeker LE; Shah G; Babady NE; Kamboj M; Seo SK
    Haematologica; 2023 Nov; 108(11):3058-3067. PubMed ID: 37345467
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of tixagevimab/cilgavimab for pre-exposure prophylaxis during the China Omicron outbreak.
    You J; Tian J; Wu H; Kang W; Wen J; Xu H; Shi W; Wang Z; Wei H; Du Y; Li X; Mu G; Zhou M; Gu Z; Qu J
    Expert Rev Anti Infect Ther; 2023; 21(12):1365-1371. PubMed ID: 37855094
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy and Safety of Tixagevimab/Cilgavimab to Prevent COVID-19 (Pre-Exposure Prophylaxis): A Systematic Review and Meta-Analysis.
    Alhumaid S; Al Mutair A; Alali J; Al Dossary N; Albattat SH; Al HajjiMohammed SM; Almuaiweed FS; AlZaid MR; Alomran MJ; Alqurini ZS; Alsultan AA; Alhajji TS; Alshaikhnasir SM; Al Motared A; Al Mutared KM; Hajissa K; Rabaan AA
    Diseases; 2022 Dec; 10(4):. PubMed ID: 36547204
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Safety and efficacy of pre-exposure prophylaxis with tixagevimab/cilgavimab (Evusheld) in patients with glomerular diseases who received rituximab.
    Sciascia S; Rilat MLA; Fenoglio R; Foddai SG; Radin M; Cecchi I; Cinnirella G; Crosasso P; Guidetti MG; Barinotti A; Baldovino S; Menegatti E; Roccatello D
    Clin Kidney J; 2023 Sep; 16(9):1465-1468. PubMed ID: 37664578
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical characteristics and COVID-19-related outcomes of immunocompromised patients receiving tixagevimab/cilgavimab pre-exposure prophylaxis in Japan.
    Taniguchi T; Homma T; Tamai Y; Arita Y; Fujiwara M; Kuroishi N; Sugiyama K; Kanazu S; Maruyama A
    J Infect Chemother; 2024 Jul; ():. PubMed ID: 38986842
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Tixagevimab + Cilgavimab: First Approval.
    Keam SJ
    Drugs; 2022 Jun; 82(9):1001-1010. PubMed ID: 35727563
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Tixagevimab/cilgavimab for prevention and treatment of COVID-19: a review.
    Ustianowski A
    Expert Rev Anti Infect Ther; 2022 Dec; 20(12):1517-1527. PubMed ID: 36217836
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Tixagevimab/Cilgavimab: Still a Valid Prophylaxis against COVID-19 New Variants?
    Gidari A; Sabbatini S; Bastianelli S; Pierucci S; Busti C; Svizzeretto E; Tommasi A; Pallotto C; Schiaroli E; Francisci D
    Viruses; 2024 Feb; 16(3):. PubMed ID: 38543720
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effectiveness of tixagevimab/cilgavimab in reducing SARS-CoV-2 infections, hospitalizations and mortality in inmunocompromised patients.
    Marti-Pastor M; Bou-Monterde R; Ciancotti-Oliver L; Alcover-Pons M; Amorós Cantero A; Sánchez-Lopezosa R; Montañana-Rosell N
    Med Clin (Barc); 2024 Sep; 163(6):275-280. PubMed ID: 38937218
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.